<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48109">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02479906</url>
  </required_header>
  <id_info>
    <org_study_id>CTP-PTSD-01</org_study_id>
    <nct_id>NCT02479906</nct_id>
  </id_info>
  <brief_title>A Safety &amp; Efficacy Study With Deep Transcranial Magnetic Stimulation for the Treatment of Post-Traumatic Stress Disorder (PTSD)</brief_title>
  <official_title>A Prospective, Double Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of the Brainsway (HAC-Coil) Deep Transcranial Magnetic Stimulation (DTMS) System for the Treatment of Post-Traumatic Stress Disorder (PTSD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brainsway</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brainsway</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present study is to evaluate the safety and efficacy of Brainsway Deep
      TMS (DTMS) for the treatment of PTSD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Deep TMS in conjunction with brief trauma exposure will be compared to sham treatment in
      conjunction with brief trauma exposure, in a multicenter, randomized, controlled study for
      the treatment of PTSD. Study duration is 9 weeks, consisting of 4 weeks of treatment and a 5
      week and 9 week follow-up visit. Subjects will be randomized to real or sham treatment
      stratified by site. The design is meant to demonstrate that the device shows superiority
      compared to sham treatment at the 5 week follow-up visit and at the 9 week follow-up visit,
      1 month post-treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CAPS-5 Score</measure>
    <time_frame>5 weeks from baseline</time_frame>
    <description>CAPS-5 Score measured by change from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>5 weeks from baseline</time_frame>
    <description>Response rate at the 5 week follow-up visit.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>5 and 9 weeks</time_frame>
    <description>Measured by vital signs, physical &amp; neurological examinations, lack of significant increase in suicide ideation, &amp; other adverse event reporting.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in Cognitive Scales</measure>
    <time_frame>5 and 9 weeks</time_frame>
    <description>Changes in MMSE and BSRT Scales</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">166</enrollment>
  <condition>Post-Traumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>Sham Treatment</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deep TMS System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deep Transcranial Magnetic Stimulation (DTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The HAC Coil is designed to stimulate neuronal pathways in the medial prefrontal cortex or motor cortex, including the anterior cingulated cortex.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Deep TMS System</intervention_name>
    <description>Deep TMS treatments will be administered 3 times a week for 4 weeks and additional 2 booster treatments at the 5 and 9 week follow-up visits, for a total of 14 treatment sessions.</description>
    <arm_group_label>Deep TMS System</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Treatment</intervention_name>
    <description>Sham treatments will be administered 3 times a week for 4 weeks and additional 2 booster treatments at the 5 and 9 week follow-up visits, for a total of 14 treatment sessions</description>
    <arm_group_label>Sham Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatients

          -  Men and women 22-68 years of age

          -  Subjects currently diagnosed with PTSD according to the DSM-5, using the CAPS-5
             (past-month version), with the following criteria met:

               -  Criterion B: at least 1/5 intrusion symptoms; and

               -  Criteria C: at least 1/2 avoidance symptoms; and

               -  Criteria D: at least 2/7 cognition &amp; mood symptoms; and

               -  Criteria E: at least 2/6 arousal &amp; reactivity symptoms; and

               -  Criterion F: duration is met; and

               -  Criteria G: distress is met.

          -  Subjects with at least moderate PTSD with a CAPS-5 score ≥ 25 at both Screening and
             Baseline visits.

          -  Subjects with an HDRS-21 score ≤ 26 at both Screening and Baseline visits.

          -  Subjects with negative or mitigated answers on safety screening questionnaire for
             transcranial magnetic stimulation.

          -  Negative pregnancy test in childbearing age women.

          -  Subject is capable and willing to provide informed consent.

          -  Subject is able to adhere to the treatment schedule.

        Exclusion Criteria:

          -  Subject diagnosed according to the SCID I as suffering from any other major Axis I
             disorder, such as Psychotic Disorder, Bipolar affective disorder, OCD (MDD is not
             contraindicated when HDRS-21≤26).

          -  Subjects diagnosed according to the SCID II as suffering from Severe Personality
             Disorder.

          -  Subjects with significant suicidal risk as assessed by the investigator using the
             Beck Suicide Ideation scale, psychiatric interview or a history of attempted suicide
             in the past year.

          -  Subject has a history of epilepsy or seizure (EXCEPT those therapeutically induced by
             ECT).

          -  Subject has a history of significant head trauma with loss of consciousness for
             longer than 5 minutes.

          -  Subject has a history of cranial surgery.

          -  Subject has metallic particles in the eye or head (exclusive of mouth), implanted
             cardiac pacemaker or any intra-cardiac lines, implanted neurostimulators,
             intra-cranial implants (e.g., aneurysm clips, shunts, stimulators, cochlear implants,
             or electrodes) or implanted medical pumps.

          -  Subject has severe and frequent headaches.

          -  Subject has a history of significant hearing loss.

          -  Subjects with a significant neurological disorder or insult including, but not
             limited to:

               -  Any condition likely to be associated with increased intracranial pressure

               -  Space occupying brain lesion

               -  History of cerebrovascular accident

               -  Transient ischemic attack within two years

               -  Cerebral aneurysm

               -  MMSE ≤ 24

               -  Parkinson's disease

               -  Huntington's chorea

               -  Multiple sclerosis

          -  Subject with a history of substance abuse including alcoholism within the past 6
             months (except nicotine and caffeine).

          -  Inadequate communication with the patient.

          -  Subject is under custodial care.

          -  Subject is currently participating in another clinical study or enrolled in another
             clinical study within 30 days prior to this study.

          -  Subject with unstable physical disease such as unstable cardiac disease.

          -  Subject is currently on Benzodiazepine at a dose higher than 3 mg of Lorazepam or
             equivalent.

          -  Subject has had previous treatment with TMS.

          -  Women who are breast-feeding.

          -  Women of childbearing potential and not using a medically accepted form of
             contraception when sexually active.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>68 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moshe Isserles, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Ein Karem Medical Center and Center for Addiction and Mental Health (CAMH)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zafiris J. Daskalakis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Addiction and Mental Health (CAMH)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Avraham Zangen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ben-Gurion University of the Negev</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amit Ezra</last_name>
    <phone>972-503103134</phone>
    <email>amite@Brainsway.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amit Ginou</last_name>
    <phone>972-526051372</phone>
    <email>amit@Brainsway.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California (UCLA)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Norman Spivak</last_name>
      <phone>310-206-5133</phone>
      <email>nspivak@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Alexander Bystritsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California - San Diego Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karin Kriger</last_name>
      <email>kkriger@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>David Feifel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06513</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Cahill</last_name>
      <email>john.cahill@yale.edu</email>
    </contact>
    <investigator>
      <last_name>John H. Krystal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Mental Health Care Inc.-Palm Beach</name>
      <address>
        <city>Florida</city>
        <state>Florida</state>
        <zip>33411</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elyssa Sisko</last_name>
      <phone>561-333-8884</phone>
      <email>elyssasisko@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Aron Tendler, MD</last_name>
      <phone>561-3338884</phone>
      <email>aron.tendler@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Aron Tendler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Mental Health Care Inc. - Juno Beach</name>
      <address>
        <city>Juno Beach</city>
        <state>Florida</state>
        <zip>33408</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elyssa Sisko</last_name>
      <phone>561-333-8884</phone>
      <email>elyssasisko@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Aron Tendler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Mental Health Care Inc. - Royal Palm Beach</name>
      <address>
        <city>Royal Palm Beach</city>
        <state>Florida</state>
        <zip>33411</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elyssa Sisko</last_name>
      <phone>561-333-8884</phone>
      <email>elyssasisko@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Aron Tendler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yellowbrick Foundation</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Viner, PhD</last_name>
      <phone>847-563-0562</phone>
      <email>LViner@yellowbrickprogram.com</email>
    </contact>
    <investigator>
      <last_name>Jesse Viner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McLean Hospital - TMS Services</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Oscar Morales, MD</last_name>
      <phone>617-855-2944</phone>
      <email>OGMORALES@PARTNERS.ORG</email>
    </contact>
    <investigator>
      <last_name>Oscar Morales</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Premier Psychiatric Group</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kelly Espenschade</last_name>
      <phone>402-476-6060</phone>
      <email>kespenschade@premierpsych.com</email>
    </contact>
    <investigator>
      <last_name>Walter J Duffy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stony Brook University</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kyle Lapidus, MD</last_name>
      <phone>631-638-1561</phone>
      <email>Kyle.Lapidus@stonybrookmedicine.edu</email>
    </contact>
    <investigator>
      <last_name>Kyle Lapidus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University Of South Carolina (MUSC)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Scott Henderson</last_name>
      <phone>843-792-5560</phone>
      <email>henderjs@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Mark George, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Senior Adults Specialty Research</name>
      <address>
        <city>Ausitn</city>
        <state>Texas</state>
        <zip>78757</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Meredith Draper, Ph.D</last_name>
      <phone>512-407-8628</phone>
      <email>mdraper@senioradults.net</email>
    </contact>
    <investigator>
      <last_name>Jaron L. Winston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8898</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Enisa Arslanagic, MD</last_name>
      <phone>214-648-8659</phone>
      <email>enisa.arslanagic@utsouthwester.edu</email>
    </contact>
    <investigator>
      <last_name>Mustafa M. Husain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Addiction and Mental Health (CAMH)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mawahib Semeralul</last_name>
      <phone>416-535-8501</phone>
      <phone_ext>30210</phone_ext>
      <email>Mawahib.Semeralul@camh.ca</email>
    </contact>
    <investigator>
      <last_name>Zafiris J. Daskalakis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beer Yaacov Mental Health Center</name>
      <address>
        <city>Beer Yaacov</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hilik Levkovitz, Prof</last_name>
      <email>yeheal@post.tau.ac.il</email>
    </contact>
    <investigator>
      <last_name>Hilik Levkovitz, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Be'er Yaacov Mental Health Center</name>
      <address>
        <city>Beer Yaakov</city>
        <zip>70350</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dikla Shmuel</last_name>
      <phone>972-54-2494688</phone>
      <email>dikla.shmuel@moh.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Yehiel Levkovitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hadasah Ein-Karem Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Omer Bonne, MD</last_name>
      <email>BONNE@hadassah.org.il</email>
    </contact>
    <investigator>
      <last_name>Omer Bonne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tel Hashomer Hospital</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tal Weisman</last_name>
      <phone>972-54-9985084</phone>
      <email>Tal.Weissman2@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Joseph Zohar, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 10, 2016</lastchanged_date>
  <firstreceived_date>June 15, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post-Traumatic Stress Disorder</keyword>
  <keyword>PTSD</keyword>
  <keyword>dTMS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
